The news sweep Thursday 21 September

The latest articles from BioStock
» Aptahem raises capital to secure development of promising sepsis treatment
» Genovis' entry ticket to the Chinese market secured
» Halozyme Therapeutics signs two agreements worth a total of SEK 16 billion
» Analysis update NeuroVive: Strong portfolio development in mitochondrial diseases
» WHO: vaccines have saved 20 million people in 20 years
» Analysis update: Idogen advances with strengthened finances and aggressive development plan
» NeuroVive organizes Mitochondria Day 2017
» German company acquired in new billion-dollar deal in immuno-oncology
» Here are the companies that have done best (and worst) since their IPO 
Read BioStock's latest newsletter for week 37 here
NeuroVive has received positive feedback from the European Medicines Agency (EMA) regarding the development plan for NeuroSTAT for the treatment of moderate to severe traumatic brain injury (TBI), including the design of the company's planned clinical proof of concept study (phase IIb). By lunchtime, the company's shares had risen approximately 28 percent on the news. Read more.
On Thursday, September 28th, BioStock Live by News Agency Direct in Stockholm, where representatives of Aptahem, Cyxone and AddMovement present their companies. The event, which will also be broadcast live online, is free of charge, but the number of seats in the TV studio is limited. Tobias Thornblad, Chief Analyst at BioStock, will present a fresh industry analysis of the Swedish Life Science sector, including post-IPO share performance, the hottest indications, current financing trends and much more that you as an investor need to keep an eye on to gain an information advantage. Read more and register here.

Trade in SenzaGens shares were launched today on Nasdaq First North. The subscription price in the previous heavily oversubscribed capital round was SEK 19,40 per share. At lunchtime, the share was trading around SEK 40 with a turnover of approximately SEK 90 million.
NextCell Pharma announces today that the company has been granted a wholesale license for cell-based study drugs. The company was inspected earlier this summer by the Swedish Medical Products Agency. The license is required for NextCell to procure, stock and distribute study drugs in the planned clinical trial with ProTrans for the treatment of diabetes. Read more.
CLS participates in the scientific conference Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting on November 8-12, 2017 in Maryland, USA, where the company will present pre-clinical work. Read more.
Sector colleague Immunicum They also join SITC to present preclinical data regarding ilixadencels mechanism of action. Read more.
Although Alligator Bioscience which develops antibody-based drug candidates for tumor-directed immunotherapy, announces today that the results from the Phase I clinical study of the drug candidate ADC-1013 will be presented at SITC. Read more.
Alligator Biosciences partnership agreement with Johnson & Johnson means that over half of the total milestone payments of $695 million will be missed before a possible approval. This emerged today after a statement by the company's CEO Per Norlén. So far, 50 million USD has been distributed from J&J. After a possible start of sales with ADC-1013, Alligator is entitled to a royalty that starts at a high single digit to a low double digit number of sales. Read more.
Surgical Science which manufactures virtual reality simulators for evidence-based keyhole surgery and endoscopic training, has appointed Anna Ahlberg as new CFO and member of the company's management team. Ahlberg has worked for many years as CFO and CIO in listed companies, mainly in international growth medical technology companies. Read more.
Karolinska Institutet: Children who develop inflammatory bowel disease (ulcerative colitis or Crohn's disease) run a doubled risk of cancer compared to people without inflammatory bowel disease, during childhood and adolescence but also later in life. The greatest increase in risk was seen for bowel cancer, but the risk was also increased for other forms of cancer such as certain forms of blood cancer and skin cancer. This is shown by a study from KI published in the prestigious journal The BMJ. Read more.
Denmark Bavarian Nordic announced this morning the first 6-month follow-up data from the Phase 2 study of MVA-BN RSV, a universal vaccine candidate designed to induce protective immune responses against subtypes A & B of respiratory syncytial virus (RSV). The randomized, placebo-controlled study evaluated the safety, tolerability and immunogenicity of the recombinant vaccine in 421 healthy adults, 55 years of age and older. Read more.
RaySearch completes a significant expansion of the RayStation platform at Princess Margaret Cancer Centre in Toronto, Canada. Read more.
Oasmia: The Nomination Committee's supplementary proposal for the 2017 Annual General Meeting. Read more.
News received yesterday afternoon:
Zenicor Medical Systems: A screening project for atrial fibrillation will begin in October at the University Hospital in Fribourg, Switzerland. The project is the first screening project with Zenicor-ECG in Switzerland. The aim is to improve care for inpatients by diagnosing atrial fibrillation in a more time- and cost-effective way than before. Read more.
Novartis announced yesterday that the drug Rydapt (midostaurin) receives EU approval for acute myeloid leukemia with FLT3 mutations, as well as three types of the rare mast cell disease advanced systemic mastocytosis (SM). Read more.
European Patent Office EPO has announced that it approves PharmaLundensis patent application for the treatment of chronic bronchitis. The patent is valid until 2032 with the possibility of an additional 5-year extension. Read more.
Alastair McEwan, COO in Danish Veloxis Pharmaceuticals, announced yesterday that he has chosen to leave his position. The search for a successor has begun. Read more.
Communiqué from the extraordinary general meeting on September 20, 2017 in WntResearch. Read more.
Winners in the lunch trade: NeuroVive +28,24%, Biovica +10,94%, Enzymatica +7,67%, SpectraCure +7,10%, Redwood Pharma +6,31%, BrainCool +6,06%
Losers in the lunch trade: Zenicor Medical Systems -8,02%, MedicPen -5,37%, Doxa -5,35%, Spago Nanomedical -5,24%, Prolight Diagnostics -5%, Vicore Pharma -4,04%
Index: OMXS30 0,43%, Healthcare 0,32%
You can also follow BioStock on Twitter and Facebook where we highlight news and research advances in life science on a daily basis